---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-26-000009"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:08:28.392809+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma appoints John Bencich as CFO, amends inducement plan by 1M shares

## Summary
- John Bencich appointed CFO effective March 9, 2026; base salary $450k, bonus target 40%.
- Equity grants: 754,717 RSUs (4-year vest) and 235,849 PSUs tied to NYSE American compliance.
- Jennifer Sy enters CAO employment agreement with $275k base, 30% bonus target, and severance terms.
- Board adds 1,000,000 shares to 2025 Inducement Plan for equity awards without stockholder approval.

## SEC filing metadata
- accession: 0001837607-26-000009
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000009/0001837607-26-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000009/aeon-20260306x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-26-000009
- JSON: https://secwatch.observer/filing/0001837607-26-000009.json
- Plain text: https://secwatch.observer/filing/0001837607-26-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.